Short answer · Medically reviewed summary · Last updated: 2026-04-06
Sjogren's syndrome was formally characterized in 1933 by Swedish ophthalmologist Henrik Sjögren, who identified the triad of keratoconjunctivitis sicca, xerostomia, and rheumatoid arthritis. The Clinical Origins of Sjogren While various physicians in the 19th century, such as Theodor von Leber and Johann von Mikulicz, described isolated cases of chronic eye and salivary gland swelling, it was Henrik Sjögren who first linked these symptoms into a cohesive clinical syndrome. He meticulously documented the ocular surface changes in 19 women, recognizing that the severe dryness was not merely an isolated eye issue but part of a systemic inflammatory process.
What is the history of Sjogren?
History of Sjogren: when and how it was discovered, and the milestones in research since, medically reviewed.
Sjogren's syndrome was formally characterized in 1933 by Swedish ophthalmologist Henrik Sjögren, who identified the triad of keratoconjunctivitis sicca, xerostomia, and rheumatoid arthritis.
The Clinical Origins of Sjogren
While various physicians in the 19th century, such as Theodor von Leber and Johann von Mikulicz, described isolated cases of chronic eye and salivary gland swelling, it was Henrik Sjögren who first linked these symptoms into a cohesive clinical syndrome. He meticulously documented the ocular surface changes in 19 women, recognizing that the severe dryness was not merely an isolated eye issue but part of a systemic inflammatory process. His seminal 1933 thesis, Zur Kenntnis der Keratoconjunctivitis sicca, remains the foundational text for understanding the disease.
Evolution of Understanding and Advocacy
For decades, Sjogren was viewed primarily as an ocular or oral condition, leading to the historical misconception that it was a localized "nuisance" disease rather than a systemic autoimmune disorder. As rheumatologists began to study the condition, the focus shifted toward its impact on the immune system, including its potential to affect the lungs, kidneys, and nervous system. The evolution of diagnostic criteria—most notably the American-European Consensus Group criteria—helped clinicians move beyond simple symptom checklists to identify the underlying autoimmune nature of Sjogren. Patient advocacy has been pivotal in this shift; organizations like the Sjogren's Foundation have transformed the perception of the disease from "dry eyes" to a serious, multisystem health challenge that requires specialized rheumatological care.
Modern Advancements
Modern medical technology has revolutionized our approach to Sjogren. While early treatment relied solely on palliative measures like artificial tears, we now utilize targeted immune-modulating therapies and biologics. Furthermore, clinical geneticists have begun to uncover the polygenic nature of Sjogren, identifying specific human leukocyte antigen (HLA) associations that predispose individuals to the disease. By integrating genomic data with clinical findings, researchers are now working toward personalized medicine, aiming to identify which patients with Sjogren are at higher risk for complications like lymphoma, thereby allowing for earlier, life-saving interventions.
Disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Sjogren's syndrome
- Orphanet: Sjogren syndrome
- Sjogren's Foundation: History and Research Milestones
